These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 1709847

  • 1. Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.
    Müller EE, Locatelli V, Ghigo E, Cella SG, Loche S, Pintor C, Camanni F.
    Drugs; 1991 Feb; 41(2):161-77. PubMed ID: 1709847
    [Abstract] [Full Text] [Related]

  • 2. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E, Imperiale E, Boffano GM, Mazza E, Bellone J, Arvat E, Procopio M, Goffi S, Barreca A, Chiabotto P.
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [Abstract] [Full Text] [Related]

  • 3. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.
    Müller EE, Rolla M, Ghigo E, Belliti D, Arvat E, Andreoni A, Torsello A, Locatelli V, Camanni F.
    Drugs; 1995 Nov; 50(5):805-37. PubMed ID: 8586028
    [Abstract] [Full Text] [Related]

  • 4. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J, Diaz MJ, Tresguerres JA, Arce V, Lima L.
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [Abstract] [Full Text] [Related]

  • 5. Regulation of hypothalamic somatostatin by glucocorticoids.
    Devesa J, Barros MG, Gondar M, Tresguerres JA, Arce V.
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):277-82. PubMed ID: 7626468
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [Abstract] [Full Text] [Related]

  • 7. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [Abstract] [Full Text] [Related]

  • 8. Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons.
    Lima L, Arce V, Diaz MJ, Tresguerres JA, Devesa J.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):439-44. PubMed ID: 8094392
    [Abstract] [Full Text] [Related]

  • 9. Comparison of growth hormone-releasing effect of growth hormone-releasing hormone, clonidine and pyridostigmine in normal children and adolescents. GH-releasing effect of GHRH, clonidine and pyridostigmine.
    Ghigo E, Arvat E, Nicolosi M, Mazza E, Camanni F.
    Panminerva Med; 1990 Feb; 32(1):1-3. PubMed ID: 2263395
    [Abstract] [Full Text] [Related]

  • 10. Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children.
    Ghigo E, Bellone J, Imperiale E, Arvat E, Mazza E, Valetto MR, Boffano GM, Cappa M, Loche S, De Sanctis C.
    Neuroendocrinology; 1990 Jul; 52(1):42-5. PubMed ID: 1697660
    [Abstract] [Full Text] [Related]

  • 11. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A, Burguera B, Casabiell X, Tresguerres JA, Dieguez C, Casanueva FF.
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [Abstract] [Full Text] [Related]

  • 12. Neurotransmitter control of growth hormone secretion in children after cranial radiation therapy.
    Jorgensen EV, Schwartz ID, Hvizdala E, Barbosa J, Phuphanich S, Shulman DI, Root AW, Estrada J, Hu CS, Bercu BB.
    J Pediatr Endocrinol; 1993 May; 6(2):131-42. PubMed ID: 8102303
    [Abstract] [Full Text] [Related]

  • 13. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.
    Hoeck HC, Vestergaard P, Jakobsen PE, Falhof J, Laurberg P.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1467-72. PubMed ID: 10770183
    [Abstract] [Full Text] [Related]

  • 14. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 15. Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs.
    Müller EE, Rolla M.
    Psychiatry Res; 1996 Apr 16; 62(1):51-63. PubMed ID: 8739115
    [Abstract] [Full Text] [Related]

  • 16. Age-dependent decrease in the growth hormone response to growth hormone-releasing hormone in normally cycling women.
    Coiro V, Volpi R, Capretti L, Caffarri G, Davoli C, Chiodera P.
    Fertil Steril; 1996 Aug 16; 66(2):230-4. PubMed ID: 8690107
    [Abstract] [Full Text] [Related]

  • 17. Hypothalamic mediation of reduced GH secretion in diabetic rats: evidence for reduced cholinergic inhibition of somatostatin release.
    Ismail I, Lewis M, Peters JR, Scanlon MF.
    J Neuroendocrinol; 1995 Apr 16; 7(4):311-8. PubMed ID: 7647774
    [Abstract] [Full Text] [Related]

  • 18. Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone.
    Arce VM, Cella SG, Locatelli V, Müller EE.
    Neuroendocrinology; 1991 May 16; 53(5):467-72. PubMed ID: 1908062
    [Abstract] [Full Text] [Related]

  • 19. Preservation of dopaminergic and alpha-adrenergic function in children with growth hormone neurosecretory dysfunction.
    Bercu BB, Root AW, Shulman DI.
    J Clin Endocrinol Metab; 1986 Oct 16; 63(4):968-73. PubMed ID: 3018032
    [Abstract] [Full Text] [Related]

  • 20. Aspects of the neuroendocrine control of growth hormone secretion in ageing mammals.
    Müller EE, Cella SG, De Gennaro Colonna V, Parenti M, Cocchi D, Locatelli V.
    J Reprod Fertil Suppl; 1993 Oct 16; 46():99-114. PubMed ID: 8100277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.